How does Telix’s Gozellix reimbursement approval change the landscape for PSMA-PET imaging in the U.S.?
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has secured a key milestone in its U.S. commercialization efforts with the announcement on July 9, 2025, that Gozellix—its next-generation PSMA-PET imaging agent—has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS). Effective from October 1, 2025, the HCPCS Level II code A9616 will enable reimbursement for Gozellix across Medicare and commercial insurance, reinforcing Telix’s ability to scale distribution and drive clinical adoption across the United States.
This regulatory advancement arrives as the Australian-headquartered radiopharmaceutical developer continues to deepen its global commercial footprint, particularly in precision oncology. The announcement follows U.S. Food and Drug Administration (FDA) approval of Gozellix in March 2025, setting up the platform for full payer integration ahead of a broader nationwide rollout.
Institutional investors viewed the reimbursement milestone as a significant accelerant for Telix’s prostate cancer imaging franchise, especially given the logistical advantages that Gozellix offers over prior-generation agents. The HCPCS designation is also seen as a precursor to potential Transitional Pass-Through (TPT) payment status—further improving provider economics in adopting the radiopharmaceutical in clinical settings.
What makes Gozellix different from Illuccix and how does it improve access to PSMA-PET diagnostics?
Gozellix is a radiopharmaceutical kit for preparing gallium-68 gozetotide injection, designed for PET imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Indications include patients with suspected metastatic disease prior to definitive therapy and those with suspected biochemical recurrence (BCR) based on elevated prostate-specific antigen (PSA) levels.
The imaging agent builds upon Telix’s first-generation product, Illuccix, which was one of the earliest gallium-68-based PSMA-PET tracers approved globally. While Illuccix helped establish PSMA-PET as a preferred diagnostic modality in prostate oncology, it had logistical challenges tied to shelf life and production workflows.
Gozellix addresses those limitations with extended shelf life and flexible production formats, making it suitable for a broader range of hospitals, imaging centers, and outpatient facilities. By overcoming geographic and technical barriers to tracer availability, Gozellix is poised to bring PSMA-PET imaging to underserved populations and secondary markets that were previously out of reach due to radioisotope decay constraints or infrastructure gaps.
Why is the HCPCS Level II code A9616 a commercial inflection point for Telix Pharmaceuticals?
The assignment of HCPCS code A9616 by CMS enables providers to bill for Gozellix services in both Medicare and private insurer workflows starting Q4 2025. Reimbursement coding is a crucial barrier in the U.S. healthcare ecosystem, especially for emerging diagnostic technologies and radiopharmaceuticals.
Securing a permanent HCPCS code is often a necessary precondition for uptake in hospital formularies, outpatient diagnostic centers, and integrated care networks. It standardizes reimbursement workflows and signals recognition from federal payers—enhancing confidence among providers, pharmacy directors, and procurement teams.
According to industry sentiment, the Gozellix HCPCS approval significantly de-risks Telix’s U.S. commercialization strategy and could translate to rapid acceleration in order volumes. Analysts expect this milestone to pave the way for revenue growth beginning in late 2025, with upside contingent on achieving additional pass-through status and possible inclusion in payer-preferred pathways.
What is the broader market potential for PSMA-PET imaging and how is Telix positioned competitively?
PSMA-PET imaging has rapidly become a new clinical standard in prostate cancer, displacing conventional imaging modalities like CT and bone scans for staging and recurrence detection. It offers superior sensitivity and specificity, enabling oncologists to tailor treatment more precisely—from localized radiation plans to systemic therapies.
In the United States, the addressable patient population for PSMA-PET imaging exceeds 200,000 annually, driven by new diagnoses and BCR monitoring. With CMS reimbursement now secured, Telix’s Gozellix enters a market with favorable macro tailwinds, including aging demographics, expanded PSA testing, and growing adoption of PET infrastructure in community oncology settings.
Telix competes with other commercial PSMA agents including Novartis’s Locametz and Blue Earth Diagnostics’ Axumin. However, Gozellix’s production flexibility, combined with Telix’s operational integration across U.S., Japan, Europe, and LATAM, gives it a differentiated go-to-market strategy focused on accessibility and reliability.
How does Gozellix’s approval align with Telix’s broader clinical and geographic expansion plans?
Telix Pharmaceuticals is aggressively building a portfolio of radiopharmaceutical agents targeting oncology and rare diseases. In addition to Illuccix and Gozellix, the biopharmaceutical developer has multiple assets in late-stage clinical development, spanning indications in renal, brain, and glioblastoma imaging.
The firm operates internationally with commercial presence in Australia, the United States, Brazil, Canada, Belgium, Switzerland, and Japan. This geographic diversification supports Telix’s ability to scale radiopharmaceutical supply chains while navigating varied regulatory regimes.
The Gozellix milestone bolsters Telix’s ambitions to become the leading platform in precision imaging and theranostics—a model that merges diagnostic PET tracers with radiotherapeutic payloads for personalized treatment regimens. Gozellix is also considered a stepping stone toward Telix’s future ambition to pair imaging and therapy through targeted alpha or beta emitters.
What do institutional investors expect following this reimbursement milestone and what are the near-term risks?
Investor sentiment has been broadly constructive following the July 2025 reimbursement announcement, as it addresses a critical bottleneck for Gozellix’s U.S. deployment. The milestone also reduces revenue volatility tied to direct sales by enabling broader access through payer channels and institutional contracts.
Analysts believe Telix’s valuation multiple could re-rate upward if Gozellix meets early adoption targets and begins contributing meaningful top-line growth by FY26. Some have flagged the potential for short-term margin pressure due to scale-up costs, salesforce deployment, and educational campaigns required to onboard imaging centers.
Regulatory uncertainty surrounding additional payment layers such as Transitional Pass-Through (TPT) status remains a watch item. Failure to secure TPT could delay profitability milestones, although the permanent HCPCS designation alone significantly de-risks adoption from an operational perspective.
What’s next for Gozellix in terms of clinical access and commercial milestones?
The HCPCS code becomes active from October 1, 2025, enabling Telix to execute its U.S. scale-up plan across regional hospital networks, independent imaging groups, and academic centers. In parallel, Telix is expected to engage with CMS and other stakeholders to pursue TPT designation, which would provide temporary additional payment for innovative technologies.
On the clinical side, Telix may expand Gozellix usage into additional PSMA-related indications pending trial outcomes and regulatory engagement. The firm is also expected to increase manufacturing capacity to support rising demand and improve lead times across major distribution hubs.
Gozellix could serve as the commercial and operational blueprint for future Telix launches in other radiopharmaceutical classes, including therapeutic isotopes that build on the same precision imaging infrastructure. Analysts expect the company’s momentum in prostate cancer imaging to drive investor focus through the rest of 2025 and into early 2026.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
